12-month study of haloperidol decanoate in chronic schizophrenic patients.
239 psychotic patients entered a 52-week open study comparing the efficacy and safety of intramuscular haloperidol decanoate, injected once every 4 weeks, with that of their previous maintenance therapy. Haloperidol decanoate, given at a medium monthly dose of 100 mg provided a suitable substitute for oral neuroleptic mono- and polytherapy and intramuscular fluphenazine decanoate. Stabilization or slight improvement was observed for all ten symptoms selected from the BPRS. The drug provoked a low incidence of side-effects allowing reduction of antiparkinsonian medication and there were no significant haematological or biochemical changes.
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
C033563:haloperidol decanoate; D006220:Haloperidol